NMPA Approval

Recombinant Human Tumor Necrosis Factor-α Receptor Ⅱ:IgG Fc Fusion Protein Injection

Approval Number

国药准字S20250003

Company杭州博之锐生物制药有限公司

Registration Date

January 8, 2025

Drug Information

Generic Name

重组人Ⅱ型肿瘤坏死因子受体-抗体融合蛋白注射液

Dosage Form

注射剂

Strength

25mg（0.5ml）/支

Drug Type

生物制品

Registration Date

January 8, 2025

Company Information

Applicant Company

Company Name杭州博之锐生物制药有限公司

Company Address

浙江省杭州市富阳区胥口镇海正路8号

Manufacturing Company

Company Name杭州博之锐生物制药有限公司

Company Address

浙江省杭州市富阳区胥口镇海正路8号

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

Product

Company

Legal

© 2025 MedPath, Inc. All rights reserved.

重组人Ⅱ型肿瘤坏死因子受体-抗体融合蛋白注射液 - NMPA 批准文号 | MedPath